<DOC>
	<DOCNO>NCT01632371</DOCNO>
	<brief_summary>The purpose study determine whether score balloon ( SCB ) plus paclitaxel-coated balloon ( PCB ) superior PCB alone treatment restenosis within `` limus '' -eluting stent ( LES )</brief_summary>
	<brief_title>Intracoronary Stenting Angiographic Results : Optimizing Treatment Drug Eluting Stent In-Stent Restenosis 4</brief_title>
	<detailed_description>The optimal treatment in-BMS-restenosis seem implantation DES support large body evidence . Nevertheless , several recent publish study show substantial reduction late lumen loss angiographic restenosis use paclitaxel-coated balloon ( PCB ) restenotic lesion . Given increase world-wide use DES use DES increasingly complex coronary disease pattern , number patient present restenosis DES implantation increase come decade . Data regard optimal treatment in-DES-restenosis limit : Implanting new DES in-DES-restenosis report associate repeat restenosis rate high 20 % . In addition , increase risk stent thrombosis associate complex stenting additional DES implantation . Thus , lesion develop restenosis LES implantation , optimal treatment strategy remain unknown . Few result small sample-size population report patient treat score cut balloon ( SCB ) technology treatment BMS restenosis compare plain balloon angioplasty . Moreover , efficacy SCB angioplasty DES restenosis adequately address . Furthermore , potential additive benefit SCB angioplasty patient undergo PCB therapy remain elucidate . The hypothesis behind concept application SCB prior deployment PCB may increase bioavailability paclitaxel within restenotic tissue , therefore may increase efficacy PCB . There numerous preclinical study support hypothesis , show lesion preparation important pre-requisite effectiveness PCB .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients ischemic symptom evidence myocardial ischemia presence ≥ 50 % restenosis prior implantation LES native coronary vessel . Written , inform consent patient her/his legallyauthorized representative participation study . In woman childbearing potential negative pregnancy test mandatory . Age &lt; 18 year Cardiogenic shock Acute STelevation myocardial infarction within 48 hour symptom onset . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . Severe renal insufficiency ( glomerular filtration rate ≤ 30 ml/min ) Contraindications antiplatelet therapy , paclitaxel , stainless steel , cobalt , chrome Therapy include Lovastatin , Ciclosporin , Terfenadine , Midazolam , Ondansetron Pregnancy ( present , suspected plan ) positive pregnancy test . Previous enrollment trial . Patient 's inability fully comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>In-stent Restenosis</keyword>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Paclitaxel Coated Balloon</keyword>
	<keyword>Scoring Balloon</keyword>
	<keyword>Cutting Balloon</keyword>
	<keyword>Angiographic follow-up</keyword>
	<keyword>Optical coherence tomography ( OCT )</keyword>
</DOC>